NCT07477366 2026-03-17
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma
ImmunityBio, Inc.
Phase 2 Not yet recruiting
Clinical Trials
14 trialsNCT07451054 2026-03-05
CD45BE-HSPC + CART-45 Cells
University of Pennsylvania
Phase 1 Not yet recruiting
NCT07101328 2026-03-04
BAF_FRontier-1
Eli Lilly and Company
Phase 1 Not yet recruiting
NCT07439653 2026-02-27
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
TORL Biotherapeutics, LLC
Phase 1/2 Not yet recruiting
NCT07283679 2026-02-24
Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Not yet recruiting
NCT07385612 2026-02-04
REFRACT-LyMA
Nantes University Hospital
Not yet recruiting
NCT07367685 2026-01-26
Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma
The Second Affiliated Hospital of Fujian Medical University
Phase 1 Not yet recruiting
NCT07049432 2026-01-23
CARMEN-803
University of Utah
Phase 1 Not yet recruiting
NCT07319676 2026-01-23
Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas
National University Hospital, Singapore
Phase 1/2 Not yet recruiting
NCT07345741 2026-01-16
Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Tongji Hospital
Phase NA Not yet recruiting
NCT07334574 2026-01-13
XP-006
Ruijin Hospital
Phase 1 Not yet recruiting
NCT07335328 2026-01-13
Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT07316920 2026-01-06
A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
Affiliated Hospital of Jiangsu University
Phase 1 Not yet recruiting
NCT07166549 2025-12-24
BaseCAR-01
University Hospital, Basel, Switzerland
Phase 1 Not yet recruiting